- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Daniel J. Klein on the Government's Role in Expanding Patient Access to Medications
Based on past efforts like the Affordable Care Act and projected future trends, some level of government intervention will be needed to help the healthcare market offer patients access and choice at an affordable price, explained Daniel J. Klein, president and CEO of the Patient Access Network Foundation.
Based on past efforts like the Affordable Care Act (ACA) and projected future trends, some level of government intervention will be needed to help the healthcare market offer patients access and choice at an affordable price, explained Daniel J. Klein, president and CEO of the Patient Access Network Foundation.
Transcript (slightly modified)
How can patient access to medications be improved? Is government intervention needed or is there another way?
Government intervention in terms of access to care has been necessary from the point of view of expanding insurance coverage. I don’t think without government intervention we would have been able to expand insurance coverage to the poor through Medicaid or to the elderly through Medicare or to people who were unable to obtain insurance in the private market, through the ACA. Clearly, the track record is that government intervention has had a big impact and a positive impact on improving access.
As far as the future goes, I think that government will continue to play a role that the market in combination with the government is probably the best solution that will optimize access and give people choice. So that’s the challenges, balancing providing universal access to healthcare coverage and providing choice, all for an affordable price. It’s no easy task, and government clearly has a role.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
